Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

Nanjing Vazyme Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	788.82	434.25	1,967	1,545	1,478	221.6
Trading Asset Securities	1,933	2,222	1,514	1,719	1,976	795.65
Cash & Short-Term Investments	2,721	2,656	3,481	3,264	3,454	1,017
Cash Growth	9.95%	-23.69%	6.65%	-5.49%	239.50%	984.22%
Accounts Receivable	499.9	483.61	351.93	839.62	322.32	226.24
Other Receivables	10.66	20.81	4.07	7.72	4.67	4.57
Receivables	510.56	504.42	356.01	847.35	326.99	230.81
Inventory	381.69	362.18	346.25	364.2	242.19	132.37
Prepaid Expenses	-	0.05	-	-	-	-
Other Current Assets	42.17	48.58	47.12	89.71	28.1	15.27
Total Current Assets	3,656	3,571	4,230	4,565	4,051	1,396
Property, Plant & Equipment	638.2	726.07	767.3	679.48	308.98	128.5
Long-Term Investments	66	54.83	47.3	22.31	18.48	-
Goodwill	130.49	130.49	130.49	130.49	-	-
Other Intangible Assets	88.78	95.19	101.24	49.7	16.65	7.42
Long-Term Accounts Receivable	0.16	0.15	-	-	-	-
Long-Term Deferred Tax Assets	171.49	146.04	106.51	67.12	24.87	9.09
Long-Term Deferred Charges	226.88	278.91	280.54	318.31	145	62.72
Other Long-Term Assets	28.65	45.51	82.53	172.69	42.25	8.22
Total Assets	5,006	5,049	5,746	6,005	4,607	1,612
Accounts Payable	66.81	90.4	146.82	318.78	118.76	58.58
Accrued Expenses	107	129.74	112.52	258.07	104.7	54.62
Short-Term Debt	696.36	551.32	1,134	272.21	-	1.15
Current Portion of Leases	39.13	57.03	46.16	58.25	31.25	-
Current Income Taxes Payable	-	0.6	0.03	0.54	20.02	31.57
Current Unearned Revenue	53.67	54.87	55.92	214.55	95.03	85.42
Other Current Liabilities	17.4	19.36	24.09	31.67	17.5	7.89
Total Current Liabilities	980.37	903.33	1,520	1,154	387.26	239.23
Long-Term Leases	126	143.36	106.89	127.68	59.93	-
Long-Term Unearned Revenue	50.91	48.38	21.38	19.25	16.24	15.36
Long-Term Deferred Tax Liabilities	0.34	1.26	1.51	11.19	0.87	0.1
Other Long-Term Liabilities	8.04	8.72	67.6	80.92	15.52	24.59
Total Liabilities	1,166	1,105	1,717	1,393	479.83	279.28
Common Stock	397.73	402.13	400.01	400.01	400.01	360
Additional Paid-In Capital	2,362	2,512	2,442	2,429	2,422	345.3
Retained Earnings	1,086	1,139	1,209	1,780	1,305	627.06
Treasury Stock	-0.97	-104.4	-20.01	-	-	-
Comprehensive Income & Other	-1.16	-3.97	-1.72	-	-	-
Total Common Equity	3,844	3,945	4,029	4,609	4,127	1,332
Minority Interest	-2.81	-1.63	-0.11	3.2	-	-
Shareholders' Equity	3,841	3,944	4,029	4,612	4,127	1,332
Total Liabilities & Equity	5,006	5,049	5,746	6,005	4,607	1,612
Total Debt	861.49	751.71	1,287	458.14	91.18	1.15
Net Cash (Debt)	1,860	1,905	2,194	2,806	3,362	1,016
Net Cash Growth	2.47%	-13.19%	-21.81%	-16.56%	230.91%	1647.85%
Net Cash Per Share	5.51	5.26	5.57	7.03	9.27	2.86
Filing Date Shares Outstanding	366.41	397.82	397	400.01	400.01	360
Total Common Shares Outstanding	366.41	397.82	397	400.01	400.01	360
Working Capital	2,675	2,668	2,711	3,411	3,664	1,156
Book Value Per Share	10.49	9.92	10.15	11.52	10.32	3.70
Tangible Book Value	3,624	3,720	3,798	4,429	4,111	1,325
Tangible Book Value Per Share	9.89	9.35	9.57	11.07	10.28	3.68
Machinery	-	712.88	656.11	513.97	250.31	119.03
Construction In Progress	-	69.42	127.48	69.44	-	36.81

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.